<DOC>
	<DOCNO>NCT02864199</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics ( area curve [ AUC ] , maximum concentration [ Cmax ] , parameter ) tolerability peginterferon alfa-2a ribavirin combination therapy follow single multiple dos participant CHC infection moderate severe renal impairment end-stage renal disease ( ESRD ) receive hemodialysis . The anticipated time study treatment 48 week , target sample size 48 individual .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a ( Pegasys ) Ribavirin ( Copegus ) Combination Therapy Participants With Chronic Hepatitis C ( CHC ) Various Degrees Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adults 18 65 year age CHC infection show enzymelinked immunosorbent assay ( ELISA ) radioimmunoblot assay ( RIBA ) quantifiable hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) great ( &gt; ) 2000 copy per milliliter ( copies/mL ) Use two form contraception study 6 month study men woman Normal renal function ( creatinine clearance [ CrCl ] &gt; 80 milliliter per minute [ mL/min ] ) , moderate renal impairment ( CrCl 30 50 mL/min ) , severe renal impairment ( CrCl less [ &lt; ] 30 mL/min ) , ESRD require hemodialysis Patients ESRD must undergo hemodialysis least 2 month Women pregnant breastfeed Male partner woman pregnant Conditions associate decompensated and/or chronic liver disease Human immunodeficiency virus ( HIV ) infection Interferon ribavirin treatment within previous 3 month Poor hematologic function , include unstable hemoglobin Significant comorbidity severe illness would make participant unsuitable study Acute renal failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>